in vitro News and Research

RSS

Thermo Fisher Scientific to acquire Phadia for €2.47 billion

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has signed a definitive agreement to acquire Phadia, a global leader in allergy and autoimmunity diagnostics, from European private equity firm Cinven, for €2.47 billion (or approximately $3.5 billion) in cash.

From Thermo Fisher Scientific Inc. 19 May 2011

Synthetic nanopatch helps regenerate natural heart tissue cells

When you suffer a heart attack, a part of your heart dies. Nerve cells in the heart's wall and a special class of cells that spontaneously expand and contract - keeping the heart beating in perfect synchronicity - are lost forever. Surgeons can't repair the affected area. It's as if when confronted with a road riddled with potholes, you abandon what's there and build a new road instead.

19 May 2011

Abbott RealTime PCR assay for measuring HCV viral load receives FDA marketing approval

Abbott announced today that it has received approval from the U.S. Food and Drug Administration to market its RealTime PCR (polymerase chain reaction) test for measuring the viral load of hepatitis C (HCV), the leading cause of liver cancer in the United States.

19 May 2011

Serpin-2 molecule may be a perfect target for preventing mosquito's immunity

Mosquitoes are becoming more resistant to current pesticides. That's troubling to Kansas State University biologist Kristin Michel, as it means malaria and other mosquito-borne diseases will continue spreading. A recent grant from the National Institutes of Health may change all that.

18 May 2011

Synergy expands GC-C agonist technology to lower cholesterol

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has successfully completed preclinical in vitro research demonstrating the inhibition of bile acid uptake by GC-C agonists and that it plans to commence animal studies shortly. Synergy believes this is the first time that GC-C agonists have been shown to potentially lower cholesterol.

18 May 2011

NCNPR and Cancer Institute in Jackson partner for anti-cancer drug research

A new partnership to search for cancer-fighting drugs combines compound-identification and screening expertise at the University of Mississippi's National Center for Natural Products Research with the drug development and clinical-trials capabilities at the University of Mississippi Medical Center Cancer Institute.

18 May 2011

Anti-cancer drug discovery partnership formed between UMMC Cancer Institute and Natural Products Center

A new partnership to search for cancer-fighting drugs combines compound-identification and screening expertise at the University of Mississippi’s National Center for Natural Products Research with the drug development and clinical-trials capabilities at the University of Mississippi Medical Center Cancer Institute.

18 May 2011

Pioneer of ‘organ-on-a-chip’ technology to speak at Imperial College London

The potential of microscopic organ-on-a-chip devices that mimic the way real organs work, so that scientists and engineers can model the effects of therapies more accurately, will be discussed by a pioneer in bioengineering at Imperial College London this week.

17 May 2011

Novel topically-applied molecular microbicide protects women against HIV infection

Using a technique that silences genes promoting infection, researchers have developed a novel, topically-applied molecular microbicide capable of preventing HIV transmission.

17 May 2011

Gene variant linked to infertility in women

A variation in a gene involved in regulating cholesterol in the bloodstream also appears to affect progesterone production in women, making it a likely culprit in a substantial number of cases of their infertility, a new study from Johns Hopkins researchers suggests.

16 May 2011

Techulon receives U.S. patent protection for Glycofect Discovery and Therapeutic Delivery Platform

Techulon, Inc. announced today that its Glycofect Discovery and Therapeutic Delivery Platform has been awarded United States patent protection. The patented invention provides a new class of non-viral transfection vectors based on synthetic carbohydrate containing polyamides that can be used for both in vivo and in vitro applications.

16 May 2011

AgenoLAB acquires Roche´s RTCA Cardio Instrument

AgenoLAB, the Stuttgart-based service provider, is the first company in Germany to expand its service offering with the latest cell analysis technology from Roche. The company will use the RTCA Cardio Instrument to complement their analytical service portfolio for drug development.

13 May 2011

New clinical data affirms safety profile of PolyMedix's PMX-30063 in treatment of Staph infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, presented new clinical and pre-clinical data related to the safety and efficacy of its novel, lead defensin-mimetic antibiotic, PMX-30063.

12 May 2011

CrystalGenomics receives draft CSR for CG400549 Phase I MAD study in Staph infections

CrystalGenomics, Inc., a biopharmaceutical company with 3 clinical stage candidates, has announced today that the draft Clinical Study Report from CG400549's Phase I Multiple Ascending Dose Study has just been received.

12 May 2011

Salmonella enterica bacterium activates virulence genes through Fur protein

Salmonella enterica, one of the main causes of gastrointestinal infections, modulates its virulence gene expression, adapting it to each stage of the infection process, depending on the free iron concentration found in the intestinal epithelium of its host.

12 May 2011

Amira to present AM152 preclinical data in fibrotic disease at ATS Annual Meeting

Amira Pharmaceuticals, Inc. announced today that it will present preclinical data on AM152, an LPA1 receptor antagonist, during the Annual Meeting of the American Thoracic Society in Denver, Colorado.

12 May 2011

Novel two-drug combination cures young patient with extensively drug-resistant tuberculosis

Belgian physicians report they have cured a young patient with extensively drug-resistant tuberculosis (XDR-TB) using a novel two-drug combination developed by researchers at Albert Einstein College of Medicine of Yeshiva University. The report, published in the Pediatric Infectious Disease Journal, marks the first known clinical use of this treatment for XDR-TB, the most deadly form of the disease.

11 May 2011

UCLA researchers amp up power of killer CD8 T-cells to fight melanoma

Researchers with UCLA's Jonsson Comprehensive Cancer Center have discovered a way to amp up the power of killer T-cells, called CD8 cells, making them more functional for longer periods of time and boosting their ability to multiply and expand within the body to fight melanoma, a new study has found.

11 May 2011

New study finds nitric oxide gas appears to affect source of sickle cell pain crises

Nitric oxide gas appears to directly impact the source of the classic, disabling pain crises of sickle cell disease, Georgia Health Sciences University researchers report.

10 May 2011

Tetraphase presents TP-434, TP-2758 antibiotics study data against pathogens at ECCMID

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results of several studies designed to support the continued advancement of its lead antibiotic, TP-434, a potent new broad-spectrum intravenous antibiotic with oral stepdown potential effective against difficult-to-treat and multidrug-resistant pathogens.

10 May 2011

in vitro News and Research

Thermo Fisher Scientific to acquire Phadia for €2.47 billion

Synthetic nanopatch helps regenerate natural heart tissue cells

Abbott RealTime PCR assay for measuring HCV viral load receives FDA marketing approval

Serpin-2 molecule may be a perfect target for preventing mosquito's immunity

Synergy expands GC-C agonist technology to lower cholesterol

NCNPR and Cancer Institute in Jackson partner for anti-cancer drug research

Anti-cancer drug discovery partnership formed between UMMC Cancer Institute and Natural Products Center

Pioneer of ‘organ-on-a-chip’ technology to speak at Imperial College London

Novel topically-applied molecular microbicide protects women against HIV infection

Gene variant linked to infertility in women

Techulon receives U.S. patent protection for Glycofect Discovery and Therapeutic Delivery Platform

AgenoLAB acquires Roche´s RTCA Cardio Instrument

New clinical data affirms safety profile of PolyMedix's PMX-30063 in treatment of Staph infections

CrystalGenomics receives draft CSR for CG400549 Phase I MAD study in Staph infections

Salmonella enterica bacterium activates virulence genes through Fur protein

Amira to present AM152 preclinical data in fibrotic disease at ATS Annual Meeting

Novel two-drug combination cures young patient with extensively drug-resistant tuberculosis

UCLA researchers amp up power of killer CD8 T-cells to fight melanoma

New study finds nitric oxide gas appears to affect source of sickle cell pain crises

Tetraphase presents TP-434, TP-2758 antibiotics study data against pathogens at ECCMID

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News